Akihiro Tamiya
About
Akihiro Tamiya is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Akihiro Tamiya has authored 110 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Pulmonary and Respiratory Medicine, 87 papers in Oncology and 14 papers in Cancer Research. Recurrent topics in Akihiro Tamiya's work include Lung Cancer Treatments and Mutations (81 papers), Lung Cancer Research Studies (36 papers) and Cancer Immunotherapy and Biomarkers (31 papers). Akihiro Tamiya is often cited by papers focused on Lung Cancer Treatments and Mutations (81 papers), Lung Cancer Research Studies (36 papers) and Cancer Immunotherapy and Biomarkers (31 papers). Akihiro Tamiya collaborates with scholars based in Japan, United States and United Kingdom. Akihiro Tamiya's co-authors include Shinji Atagi, Yoshihiko Taniguchi, Motohiro Tamiya, Kyoichi Okishio, Tomonori Hirashima, Shun‐ichi Isa, Takayuki Shiroyama, Kenji Nakahama, Tomoya Kawaguchi and Fumio Imamura and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.
In The Last Decade
Akihiro Tamiya
107 papers receiving 1.8k citations
Peers
Akihiro Tamiya
Diego Signorelli Italy
Uliano Morandi Italy
Marc Matrana United States
Assuntina G. Sacco United States
Yukinori Murata Japan
T. V. Colby United States
Tomohiro Haruki Japan
Michael Schenker Romania
Konstantinos Linos United States
Marcus Tan United States
Citations per year, relative to Akihiro Tamiya Akihiro Tamiya (= 1×)
peers
Diego Signorelli
Countries citing papers authored by Akihiro Tamiya
Since
Specialization
Citations
This map shows the geographic impact of Akihiro Tamiya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akihiro Tamiya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akihiro Tamiya more than expected).
Fields of papers citing papers by Akihiro Tamiya
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Akihiro Tamiya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akihiro Tamiya. The network helps show where Akihiro Tamiya may publish in the future.
Co-authorship network of co-authors of Akihiro Tamiya
This figure shows the co-authorship network connecting the top 25 collaborators of Akihiro Tamiya. A scholar is included among the top collaborators of Akihiro Tamiya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akihiro Tamiya. Akihiro Tamiya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Miyamoto, Shimpei, Hanako Kuhara, Takayuki Shiroyama, et al.. (2025). Real‐World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan. Thoracic Cancer. 16(6). e70047–e70047.
2.
Matsumoto, Kinnosuke, Akihiro Tamiya, Motohiro Tamiya, et al.. (2025). Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study. European Journal of Cancer. 228. 115748–115748.
3.
Tamiya, Akihiro, Daijiro Harada, Shun‐ichi Isa, et al.. (2024). Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer. Lung Cancer. 195. 107917–107917.
4.
Matsumoto, Kinnosuke, Yuji Yamamoto, Takayuki Shiroyama, et al.. (2024). Risk Stratification According to Baseline and Early Change in Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Treated with Chemoimmunotherapy: A Multicenter Real-World Study. Targeted Oncology. 19(5). 757–767.
5.
Taniguchi, Yoshihiko, Akihiro Tamiya, Atsushi Yanagisawa, et al.. (2023). Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF‐V600E ‐positive non–small cell lung cancer: A case report. Thoracic Cancer. 14(13). 1201–1203.
6.
Inagaki, Yuji, Yoshihiko Taniguchi, Keiko Nakao, et al.. (2023). Right‐sided vocal cord paralysis following stereotactic body radiation therapy for non–small‐cell lung cancer: A case report. Thoracic Cancer. 14(16). 1534–1537.
7.
Tamiya, Akihiro, Yuji Inagaki, Yoshihiko Taniguchi, et al.. (2023). Enhancing tumour content and tumour cell count using microdissection contributes to higher detection rate of genetic mutations by next-generation sequencers. Heliyon. 9(11). e22082–e22082.
8.
Arai, Toru, Hiromitsu Sumikawa, Takayuki Takimoto, et al.. (2023). Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer Patients with Interstitial Lung Disease: Significance of Radiological Pleuroparenchymal Fibroelastosis. Oncology. 101(5). 303–312.
9.
Matsumoto, Kinnosuke, Akihiro Tamiya, Yuji Inagaki, et al.. (2021). Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer: A multicenter retrospective cohort study. Journal of Geriatric Oncology. 13(2). 207–213.
10.
Inagaki, Yuji, Akihiro Tamiya, Yoshinobu Matsuda, et al.. (2020). Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma. Medicine. 99(42). e22628–e22628.
11.
Tamiya, Akihiro, Masahiro Morimoto, Kyoichi Okishio, et al.. (2018). A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer. Investigational New Drugs. 36(4). 667–673.
12.
Shiroyama, Takayuki, Hidekazu Suzuki, Motohiro Tamiya, et al.. (2018). Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer. Anticancer Research. 38(8). 4723–4729.
13.
Kaneda, Toshihiko, Hiroshige Yoshioka, Motohiro Tamiya, et al.. (2018). Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer. BMC Cancer. 18(1). 6–6.
14.
Yang, James Chih‐Hsin, Yi‐Long Wu, Vera Hirsh, et al.. (2018). 143PD Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7. Journal of Thoracic Oncology. 13(4). S84–S85.
15.
Taniguchi, Yoshihiko, N. Saijo, Akihiro Tamiya, et al.. (2017). The efficacy of a reduced dose (40mg) of osimertinib with T790M-positive advanced non-small-cell lung cancer. Annals of Oncology. 28. x130–x130.
16.
Morimoto, Masahiro, Kyoichi Okishio, Masanori Akira, et al.. (2016). Duration of Twice-Daily Thoracic Radiotherapy and Time From the Start of Any Treatment to the End of Chest Irradiation as Significant Predictors of Outcomes in Limited-Disease Small-Cell Lung Cancer. Clinical Lung Cancer. 18(2). e117–e127.
17.
Watanabe, Masaru, Tomoya Kawaguchi, Shun‐ichi Isa, et al.. (2015). Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR. Clinical Cancer Research. 21(15). 3552–3560.
18.
Asami, Kazuhiro, Masaaki Kawahara, Tomonori Hirashima, et al.. (2014). Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non‐squamous cell non‐small cell lung cancer in J apan. Thoracic Cancer. 5(4). 289–296.
19.
Omachi, Naoki, Shigeki Shimizu, Tomoya Kawaguchi, et al.. (2014). A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4–ALK Rearrangement with Resistance to the ALK Inhibitor Crizotinib. Journal of Thoracic Oncology. 9(6). e40–e42.
20.
Tamiya, Akihiro, Motohiro Tamiya, Takayuki Shiroyama, et al.. (2012). Dose escalation study of carboplatin–pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. Annals of Oncology. 24(4). 980–985.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Diego Signorelli Breakdown of academic impact, for papers by Uliano Morandi Breakdown of academic impact, for papers by Marc Matrana Breakdown of academic impact, for papers by Assuntina G. Sacco Breakdown of academic impact, for papers by Yukinori Murata Breakdown of academic impact, for papers by T. V. Colby Breakdown of academic impact, for papers by Tomohiro Haruki Breakdown of academic impact, for papers by Michael Schenker Breakdown of academic impact, for papers by Konstantinos Linos Breakdown of academic impact, for papers by Marcus Tan